ReviewESMO open2019
Cancer medicines in Asia and Asia-Pacific: What is available, and is it effective enough?
Review in ESMO open, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 44 citations in OpenAlex.
- Adverse drug reactions associated with doxorubicin and epirubicin: A descriptive analysis from VigiBase.Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners · 2026Article
- Caution over haste: why novel endocrine therapy in early lines should wait in Estrogen receptor positive human epidermal growth factor receptor 2 negative breast cancer.Breast cancer research : BCR · 2026Review
- Disparities in access to systemic therapies for patients with hepatocellular carcinoma: an analysis from the International Liver Cancer Association.The Lancet regional health. Europe · 2025Review
- Patent landscape of nanotechnology - based nucleic acid delivery systems for breast cancer therapies.Frontiers in oncology · 2025Article
- A comparison of clinical guidelines, treatment characteristics and outcomes in small cell lung cancer between East Asia and Europe/North America.Frontiers in oncology · 2025Review
- Quantitative evaluation of dual-channel drug supply policy on nationally negotiated anti-tumor drugs in Xuzhou: based on interrupted time series analysis.Frontiers in pharmacology · 2025Article
- Liver diseases and hepatocellular carcinoma in the Asia-Pacific region: burden, trends, challenges and future directions.Nature reviews. Gastroenterology & hepatology · 2024Review
- Drug development and evidence for lung cancer targeted therapy in Eastern Asia.The Lancet regional health. Western Pacific · 2024Review
- Biosimilars in the Era of Artificial Intelligence-International Regulations and the Use in Oncological Treatments.Pharmaceuticals (Basel, Switzerland) · 2024Review
- Monoclonal antibody biosimilars for cancer treatment.iScience · 2024Review
- Clinical application of liquid biopsy genomic profiling in NSCLC: Asian perspectives.The journal of liquid biopsy · 2024Review
- Cancer burden across the South Asian Association for Regional Cooperation in 2022.BMJ oncology · 2024Article
- Cancer Care in Afghanistan: Perspectives on Health Services Under the Taliban Regime.JCO global oncology · 2023Article
- Overall survival benefits of cancer drugs in the WHO Model List of Essential Medicines, 2015-2021.BMJ global health · 2023Article
- Advancing Cardio-Oncology in Asia.Korean circulation journal · 2023Review
- Barriers and Facilitators of Adherence to Oral Anticancer Medications Among Women with Breast Cancer: A Qualitative Study.Patient preference and adherence · 2023Article
- Healthcare coverage affects survival ofFrontiers in oncology · 2023Article
- Globalisation of industry-sponsored clinical trials for breast, lung and colon cancer research: trends, threats and opportunities.BMJ oncology · 2023Article
- Fighting Cancer around the World: A Framework for Action.Healthcare (Basel, Switzerland) · 2022Article
- Clinical evidence and insights supporting the use of avelumab first-line maintenance treatment in patients with advanced urothelial carcinoma in the Asia-Pacific region.Asia-Pacific journal of clinical oncology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 5 countries.
Funding
Abstract
This review article is an overview of the session at the European Society for Medical Oncology (ESMO) Asia 2018 Congress entitled: 'Cancer medicines in Asia and Asia-Pacific: What is available, and is it effective enough?'. The article provides an overview of the session speakers' views on the impact that the lack of accessibility and availability of medicines has on patient outcomes in the treatment of breast cancer, colorectal cancer and lung cancer, responsible for more than one-third of cancer deaths in the Asian region. It also lists the various global policy initiatives that ESMO supports to promote the best cancer care in the Asian and Asia-Pacific region. The review presents extrapolated data from the 'ESMO International Consortium Study on the availability, out-of-pocket costs and accessibility of antineoplastic medicines in countries outside of Europe', which reveals several disparities among Asian countries, across the different income levels. In low- and middle-income countries, some barriers to the accessibility of anticancer medicines include the lack of government reimbursement, budget allocation for healthcare and quality-assured generic and biosimilar medicines, as well as shortages and patent rights. Throughout the article, the session presenters provide their views on strategies that can be considered to overcome these barriers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.